Last night's positive Phase II data for Viaskin Milk in patients with allergy to cow's milk protein supports the Viaskin platform, but focus remains on DBV Technologies' regulatory process for peanut allergy, Deutsche Bank analyst Andrew Peters says in a research note. The analyst thinks the Miles data are potentially supportive of the overall platform as well as also represent an additional opportunity for the company. He notes that although benefits were observed for children ages 2-11, the treatment did not show a meaningful effect in adolescents, which is similar to the results with Viaskin Peanut. This is potentially indicative of some challenges to the applicability of Viaksin in older patients or indicating the need for further fine-tuning of dose and patch, Peters writes. He reiterates a Buy rating on DBV Technologies with a $30 price target. The analyst believes Viaskin Peanut provides an "attractive risk/benefit" to peanut allergy patients and that the implied risk at current share levels is "overly cautious."